BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity

• Published in: Journal of immunology research 2022-07, Vol.2022, p.1-20
• Main Authors: Liu, Junxiu, Tian, Tian, Liu, Xiangyu, Cui, Zhumei
• Format: Article
• Language: English
• Subjects: Biomarkers; Cancer immunotherapy; Carcinoma; CD28 antigen; CD4 antigen; Endometrial cancer; Endometrium; Gene expression; Gene set enrichment analysis; Genetic analysis; Genomes; Hepatocytes; Immune checkpoint; Immune system; Immunohistochemistry; Immunology; Immunoregulation; Immunotherapy; Lymphocytes T; Malignancy; Medical prognosis; Microsatellite instability; Mutation; Neoantigens; PD-1 protein; Prognosis; Protein expression; Protein interaction; Proteins; Survival analysis; Tumor microenvironment; Tumors; Uterine cancer
• ISSN: 2314-8861; 2314-7156
• DOI: 10.1155/2022/6051092

Background. In developed countries, the most common gynecologic malignancy is endometrial carcinoma (EC), making the identification of EC biomarkers extremely essential. As a natural enzyme, butyrylcholinesterase (BCHE) is found in hepatocytes and plasma. There is a strong correlation between BCHE gene mutations and cancers and other diseases. The aim of this study was to analyze the role of BCHE in patients with EC. Methods. A variety of analyses were conducted on The Cancer Genome Atlas (TCGA) data, including differential expression analysis, enrichment analysis, immunity, clinicopathology, and survival analysis. The Gene Expression Omnibus (GEO) database was used to validate outcomes. Using R tools, Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) analyses revealed the potential mechanisms of BCHE in EC. Sangerbox tools were used to delve into the relations between BCHE expression and tumor microenvironment, including microsatellite instability (MSI), tumor neoantigen count (TNC), and tumor mutation burden (TMB). BCHE’s genetic alteration analysis was conducted by cBioPortal. In addition, the Human Protein Atlas (HPA) was used to validate the outcomes by immunohistochemistry, and an analysis of the protein-protein interaction network (PPI) was performed with the help of the STRING database. Results. Based on our results, BCHE was a significant independent prognostic factor for patients with EC. The prognosis with EC was affected by age, stage, grade, histological type, and BCHE. GSEA showed that BCHE was closely related to pathways regulating immune response, including transforming growth factor-β (TGF-β) signaling pathways and cancer immunotherapy through PD1 blockade pathways. The immune analysis revealed that CD4+ regulatory T cells (Tregs) were negatively correlated with BCHE expression and the immune checkpoint molecules CD28, ADORA2A, BTNL2, and TNFRSF18 were all significantly related to BCHE. BCHE expression was also associated with TMB by genetic alteration analysis. Conclusions. Identifying BCHE as a biomarker for EC might help predict its prognosis and could have important implications for immunotherapy.